Short Interest in Prestige Consumer Healthcare Inc. (NYSE:PBH) Declines By 18.8%

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) was the target of a significant decline in short interest in the month of February. As of February 15th, there was short interest totalling 1,680,000 shares, a decline of 18.8% from the January 31st total of 2,070,000 shares. Based on an average daily trading volume, of 286,900 shares, the short-interest ratio is presently 5.9 days. Approximately 3.4% of the company's shares are short sold.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Large investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC increased its position in shares of Prestige Consumer Healthcare by 3.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,624,501 shares of the company's stock worth $126,274,000 after purchasing an additional 49,331 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Prestige Consumer Healthcare by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 1,348,745 shares of the company's stock worth $105,342,000 after purchasing an additional 21,951 shares in the last quarter. Kayne Anderson Rudnick Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth $84,932,000. Invesco Ltd. increased its position in shares of Prestige Consumer Healthcare by 2.4% during the fourth quarter. Invesco Ltd. now owns 1,060,263 shares of the company's stock worth $82,796,000 after purchasing an additional 24,392 shares in the last quarter. Finally, Congress Asset Management Co. increased its position in shares of Prestige Consumer Healthcare by 5.0% during the fourth quarter. Congress Asset Management Co. now owns 908,742 shares of the company's stock worth $70,964,000 after purchasing an additional 43,619 shares in the last quarter. Institutional investors own 99.95% of the company's stock.

Remove Ads

Prestige Consumer Healthcare Stock Up 2.3 %

NYSE:PBH traded up $2.01 during trading hours on Friday, reaching $89.10. The company's stock had a trading volume of 604,737 shares, compared to its average volume of 328,521. The company has a market capitalization of $4.41 billion, a P/E ratio of 20.87, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare has a 12 month low of $62.35 and a 12 month high of $89.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The stock has a 50 day moving average price of $80.80 and a two-hundred day moving average price of $77.83.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PBH shares. Sidoti lowered Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price target for the company. in a report on Monday, December 9th. DA Davidson boosted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Oppenheimer boosted their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Canaccord Genuity Group boosted their price target on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th. Finally, StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of "Moderate Buy" and an average price target of $92.60.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.